Evaluation of Radiolabeled Girentuximab In Vitro and In Vivo
AbstractGirentuximab (cG250) targets carbonic anhydrase IX (CAIX), a protein which is expressed on the surface of most renal cancer cells (RCCs). cG250 labeled with 177Lu has been used in clinical trials for radioimmunotherapy (RIT) of RCCs. In this work, an extensive characterization of the immunoconjugates allowed optimization of the labeling conditions with 177Lu while maintaining immunoreactivity of cG250, which was then investigated in in vitro and in vivo experiments. cG250 was conjugated with S-2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane tetraacetic acid (DOTA(SCN)) by using incubation times between 30 and 90 min and characterized by mass spectrometry. Immunoconjugates with five to ten DOTA(SCN) molecules per cG250 molecule were obtained. Conjugates with ratios less than six DOTA(SCN)/cG250 had higher in vitro antigen affinity, both pre- and postlabeling with 177Lu. Radiochemical stability increased, in the presence of sodium ascorbate, which prevents radiolysis. The immunoreactivity of the radiolabeled cG250 tested by specific binding to SK-RC-52 cells decreased when the DOTA content per conjugate increased. The in vivo tumor uptake was < 10% ID/g and independent of the total amount of protein in the range between 5 and 100 µg cG250 per animal. Low tumor uptake was found to be due to significant necrotic areas and heterogeneous CAIX expression. In addition, low vascularity indicated relatively poor accessibility of the CAIX target. View Full-Text
- Supplementary File 1:
ZIP-Document (ZIP, 5200 KB)
Share & Cite This Article
Basaco, T.; Pektor, S.; Bermudez, J.M.; Meneses, N.; Heller, M.; Galván, J.A.; Boligán, K.F.; Schürch, S.; Von Gunten, S.; Türler, A.; Miederer, M. Evaluation of Radiolabeled Girentuximab In Vitro and In Vivo. Pharmaceuticals 2018, 11, 132.
Basaco T, Pektor S, Bermudez JM, Meneses N, Heller M, Galván JA, Boligán KF, Schürch S, Von Gunten S, Türler A, Miederer M. Evaluation of Radiolabeled Girentuximab In Vitro and In Vivo. Pharmaceuticals. 2018; 11(4):132.Chicago/Turabian Style
Basaco, Tais; Pektor, Stefanie; Bermudez, Josue M.; Meneses, Niurka; Heller, Manfred; Galván, José A.; Boligán, Kayluz F.; Schürch, Stefan; Von Gunten, Stephan; Türler, Andreas; Miederer, Matthias. 2018. "Evaluation of Radiolabeled Girentuximab In Vitro and In Vivo." Pharmaceuticals 11, no. 4: 132.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.